We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II open-label study of single-agent hydroxyurea for treatment of mast cell tumours in dogs.
- Authors
Rassnick, K. M.; Al-Sarraf, R.; Bailey, D. B.; Chretin, J. D.; Phillips, B.; Zwhalen, C. H.
- Abstract
This prospective study evaluated the efficacy and safety of hydroxyurea (HU) in dogs with measurable mast cell tumours (MCTs). Dogs were treated with HU at 60 mg kg−1 per os q24h for 14 days then 30 mg kg−1 q24h thereafter or until MCT recurrence. Forty-six dogs were enrolled. The overall response rate was 28%. Two dogs had a complete response (CR) for 256 and 448 days, respectively. Eleven dogs had a partial response for a median duration of 46 days (range, 28–189 days). Grade 2 to 4 neutropenia occurred in eight dogs and grade 4 thrombocytopenia in two. Grade 3–4 anaemia occurred in seven dogs; overall, there was a significant decrease in haematocrit after treatment with HU. The median drop in haematocrit was 10%. This study demonstrated that HU has activity in the treatment of MCTs with mild anaemia being the primary adverse event.
- Subjects
HYDROXYUREA; BLOOD diseases; BLOOD platelet disorders; THROMBOCYTOPENIA; ERYTHROCYTES
- Publication
Veterinary & Comparative Oncology, 2010, Vol 8, Issue 2, p103
- ISSN
1476-5810
- Publication type
Article
- DOI
10.1111/j.1476-5829.2010.00211.x